WP1130 Enhances TRAIL-Induced Apoptosis through USP9X-Dependent miR-708-Mediated Downregulation of c-FLIP
Explore this paper's citation graph
Summary
WP1130 sensitized TRAIL-induced apoptosis through miR-708-mediated downregulation of c-FLIP by inhibition of USP9X, and thereby sensitized TNF-related apoptosis-inducing ligand (TRAIL)- induced apoptosis in human renal carcinoma cells.
- Type
- article
- Published
- 2019-03-01
- Cited by
- 43
- References
- 47
- Access
- Open access
- OpenAlex
- https://openalex.org/W2921528227
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:76666977
Keywords
Downregulation and upregulation, Apoptosis, Flip, Gene knockdown, Cancer research
References
- Otubains: a new family of cysteine proteases in the ubiquitin pathway
- USP9X inhibition promotes radiation-induced apoptosis in non-small cell lung cancer cells expressing mid-to-high MCL1
- Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells.
- Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis.
- The Akt-regulated Forkhead Transcription Factor FOXO3a Controls Endothelial Cell Viability through Modulation of the Caspase-8 Inhibitor FLIP*
- The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition
- TRAIL signalling: decisions between life and death.
- Doxorubicin Pretreatment Sensitizes Prostate Cancer Cell Lines to TRAIL Induced Apoptosis Which Correlates with the Loss of c-FLIP Expression
- The ubiquitin-proteasome proteolytic pathway.
- Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies.
- p53 upregulates cFLIP, inhibits transcription of NF-κB-regulated genes and induces caspase-8-independent cell death in DLD-1 cells
- An antagonist decoy receptor and a death domain-containing receptor for TRAIL.
- WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation.
- Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter.
- The ubiquitin-proteasome system
- MicroRNA-708 induces apoptosis and suppresses tumorigenicity in renal cancer cells
- Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors.
- mTOR complex 2 is involved in regulation of Cbl-dependent c-FLIP degradation and sensitivity of TRAIL-induced apoptosis
- Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis.
- Involvement of FLIP in 2-methoxyestradiol induced tumor regression in transgenic adenocarcinoma of mouse prostate (TRAMP) model
Cited by
- Targeting USP9x/SOX2 axis contributes to the anti-osteosarcoma effect of neogambogic acid
- Emerging role of ubiquitin-specific protease 14 in oncogenesis and development of tumor: Therapeutic implication.
- Structure and function of USP5: Insight into physiological and pathophysiological roles.
- Honokiol Enhances TRAIL-Mediated Apoptosis through STAMBPL1-Induced Survivin and c-FLIP Degradation
- Hispidulin Enhances TRAIL-Mediated Apoptosis via CaMKKβ/AMPK/USP51 Axis-Mediated Bim Stabilization
- TRAIL mediated signaling as a double-edged sword in pancreatic cancer: Analysis of brighter and darker sides of the pathway.
- Evaluation of MiR-1908-3p as a novel serum biomarker for breast cancer and analysis its oncogenic function and target genes
- Dexamethasone Inhibits TRAIL-Induced Apoptosis through c-FLIP(L) Upregulation and DR5 Downregulation by GSK3β Activation in Cancer Cells
- Inhibition of Drp1 Sensitizes Cancer Cells to Cisplatin-Induced Apoptosis through Transcriptional Inhibition of c-FLIP Expression
- Emerging role of ubiquitination in the regulation of PD-1/PD-L1 in cancer immunotherapy.
- Stabilization of EGLN3 by USP9X Contributes to Antineoplastic Function in Cholangiocarcinoma
- USP9X promotes apoptosis in cholangiocarcinoma by modulation expression of KIF1Bβ via deubiquitinating EGLN3
- A combination of sorafenib and radiotherapy reduces NF-κB activity and growth of hepatocellular carcinoma in an orthotopic mouse model
- Inhibition of cathepsin K sensitizes oxaliplatin-induced apoptotic cell death by Bax upregulation through OTUB1-mediated p53 stabilization in vitro and in vivo
- Melatonin induces apoptotic cell death through Bim stabilization by Sp1‐mediated OTUD1 upregulation
- A review on the treatment of multiple myeloma with small molecular agents in the past five years.
- Regulation of extrinsic apoptotic signaling by c-FLIP: towards targeting cancer networks.
- Pro-apoptotic and anti-apoptotic regulation mediated by deubiquitinating enzymes
- Evidence that BJcuL, a C-type lectin from Bothrops jararacussu venom, influences deubiquitinase activity, resulting in the accumulation of anti-apoptotic proteins in two colorectal cancer cell lines.
- TGFBR2 is a novel substrate and indirect transcription target of deubiquitylase USP9X in granulosa cells
Related papers
- Knockdown of LIMD2 inhibits the progression of ovarian carcinoma through ERK1/2 pathway
- Knockdown of ecdysteroid synthesis genes results in impaired molting and high mortality in Bactericera cockerelli (Hemiptera: Triozidae).
- Supplementary Revised Figure S3 from MUC16 Regulates TSPYL5 for Lung Cancer Cell Growth and Chemoresistance by Suppressing p53
- Downregulation of miR-140-3p Is a Cause of Upregulation of RhoA Protein in Bronchial Smooth Muscle of Murine Experimental Asthma.
- Downregulation of circEPSTI1 represses the proliferation and invasion of non-small cell lung cancer by inhibiting TRIM24 via miR-1248 upregulation.
- Upregulation of NFE2L1 reduces ROS levels and α-synuclein aggregation caused by GBA1 knockdown.
- EP News: Basic and Translational
- Activating Mas receptor protects human pulmonary microvascular endothelial cells against LPS‐induced apoptosis via the NF‐kB p65/P53 feedback pathways
- Inhibition of HER Receptors Reveals Distinct Mechanisms of Compensatory Upregulation of Other HER Family Members: Basis for Acquired Resistance and for Combination Therapy